Insider Selling: Moderna, Inc. (NASDAQ:MRNA) President Sells 15,000 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the transaction, the president now directly owns 1,486,241 shares in the company, valued at $156,085,029.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Stephen Hoge also recently made the following trade(s):

• On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The stock was sold at an average price of $94.57, for a total value of $225,833.16.

Moderna Stock Down 0.3 %

Shares of NASDAQ MRNA traded down $0.35 during mid-day trading on Wednesday, hitting $103.44. The company had a trading volume of 1,999,889 shares, compared to its average volume of 4,213,013. The company has a market capitalization of $39.61 billion, a PE ratio of -8.36 and a beta of 1.62. The business's 50-day simple moving average is $100.10 and its 200 day simple moving average is $93.52. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $144.93. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. Moderna's revenue was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.61 EPS. On average, analysts predict that Moderna, Inc. will post -7.51 earnings per share for the current year.

Institutional Trading of Moderna

Several hedge funds have recently added to or reduced their stakes in the company. ICA Group Wealth Management LLC acquired a new stake in shares of Moderna in the 4th quarter valued at $27,000. First Pacific Financial acquired a new stake in Moderna in the third quarter valued at $27,000. Ogorek Anthony Joseph NY ADV purchased a new stake in Moderna during the 4th quarter worth about $27,000. Arlington Trust Co LLC boosted its position in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock worth $29,000 after acquiring an additional 290 shares in the last quarter. Finally, Rise Advisors LLC boosted its position in shares of Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company's stock worth $34,000 after acquiring an additional 286 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on MRNA shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a research note on Thursday, April 11th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, April 1st. HSBC reiterated a "reduce" rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Jefferies Financial Group restated a "buy" rating and issued a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. Finally, Oppenheimer upgraded shares of Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 target price for the company in a report on Tuesday, January 2nd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Moderna currently has a consensus rating of "Hold" and an average target price of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.